NewcelX Ltd. (NCEL)
NASDAQ: NCEL · Real-Time Price · USD
3.640
+0.030 (0.83%)
At close: Dec 5, 2025, 4:00 PM EST
3.330
-0.310 (-8.52%)
After-hours: Dec 5, 2025, 5:40 PM EST
NewcelX Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
16.59M USD
Revenue Chart
* This company reports financials in ILS.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NCEL News
- 19 days ago - NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute - PRNewsWire
- 4 weeks ago - NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board - PRNewsWire
- 4 weeks ago - NewcelX CEO Issues Letter to Shareholders - PRNewsWire
- 4 weeks ago - NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. - PRNewsWire